Stock Detail
Sector:
Latest Quote @ Tue May 5 17:34:04 (15 min delayed)
| N/A |
N/A |
$0.692 |
+0.00 |
0.00% |
|
Last Day's Data
| $0.00 |
$0.00 |
$0.00 |
0.00% |
0.00 |
$0.00 |
| $0.00 |
$0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Stock Profile
Nabi Biopharmaceuticals engages in the development and commercialization of products in the areas of Gram-positive bacterial infections, hepatitis, nephrology, and nicotine addiction. The company markets three products: PhosLo for treatment of hyperphosphatemia in end-stage renal failure patients; Nabi-HB for the prevention of hepatitis B infections; and Aloprim for the treatment of chemotherapy-induced hyperuricemia or high uric acid levels. Nabi also has products in various stages of clinical and preclinical development. Its advanced StaphVAX, which is in Phase III clinical development, is designed to prevent the most dangerous and prevalent strains of Staphylococcus aureus bacterial infections. The company's other products in development include Altastaph, an antibody for prevention of Staphylococcus aureus infections; NicVAX, a vaccine to treat nicotine addiction; and Civacir, an antibody for preventing hepatitis C virus reinfection in liver transplant patients. The company also offers contract manufacturing services. Nabi sells its biopharmaceutical products to wholesalers, distributors, hospitals, and home healthcare companies, as well as sells its antibody products to pharmaceutical and diagnostic product manufacturers. The company has strategic alliances with Public Health Services/National Institutes of Health; Chiron Corporation; Pfizer; and Cambrex BioScience of Baltimore, Inc. Nabi is headquartered in Boca Raton, Florida.
